What it's for (Indications)
- Vancomycin is a glycopeptide antibiotic primarily indicated for the treatment of serious and potentially life-threatening infections caused by susceptible Gram-positive bacteria, particularly those resistant to other commonly used antibiotics.
- Key indications include methicillin-resistant *Staphylococcus aureus* (MRSA) infections, such as endocarditis, osteomyelitis, pneumonia, septicemia, and skin and soft tissue infections.
- It is also utilized in the management of infections caused by other Gram-positive organisms, including *Clostridium difficile*-associated diarrhea (CDAD) when administered orally, and certain enterococcal infections.
- Additionally, vancomycin may be used for surgical prophylaxis in specific high-risk scenarios, especially in institutions with high rates of MRSA or in patients with known allergies to beta-lactam antibiotics.
- Its broad utility against multi-drug resistant Gram-positive pathogens makes it a cornerstone of anti-infective therapy in critical care settings and for complex infections.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage regimens for vancomycin are highly individualized, factoring in the patient's age, weight, renal function, severity of infection, and the specific site of infection. For intravenous administration in adults, typical dosages range from 15 to 20 mg/kg per dose, administered every 8 to 12 hours, with a maximum single dose of 2 grams. Therapeutic drug monitoring (TDM) is crucial for intravenous vancomycin, aiming for target trough concentrations (usually 10-20 mcg/mL, or higher for severe infections) to ensure efficacy and minimize toxicity. Dosing must be carefully adjusted in patients with impaired renal function, guided by creatinine clearance. For *Clostridioides difficile*-associated diarrhea, the oral dosage for adults is typically 125 mg to 500 mg, four times daily, for 10 to 14 days. Pediatric dosing is weight-based and requires similar attention to renal function and TDM. Close monitoring is essential to optimize outcomes and prevent adverse effects. |
Safety & Warnings
Common Side Effects
- Vancomycin can cause a range of side effects, some of which are serious and require careful monitoring.
- The most well-known acute adverse reaction is 'Red Man Syndrome' (RMS), an infusion-related reaction characterized by flushing, erythema, pruritus, urticaria, tachycardia, and hypotension, typically associated with rapid intravenous infusion.
- This is a histamine-mediated reaction, not an allergic one, and can be mitigated by slowing the infusion rate and/or administering antihistamines.
- Nephrotoxicity, manifested by acute kidney injury, is a significant concern, especially with high trough levels, prolonged therapy, or concomitant use of other nephrotoxic agents.
- Ototoxicity, leading to hearing loss or tinnitus, is rare but can occur, particularly with elevated trough concentrations or in patients receiving other ototoxic drugs.
- Other potential side effects include hypersensitivity reactions (e.
- g.
- , rash, fever, eosinophilia, anaphylaxis), neutropenia, thrombocytopenia, phlebitis at the injection site, and superinfection with non-susceptible organisms.
Serious Warnings
- Black Box Warning: Vancomycin does not carry a formal FDA-mandated Black Box Warning. However, clinicians must be acutely aware of several serious risks that necessitate meticulous monitoring and management. These 'Serious Warnings' include the potential for significant nephrotoxicity, which can manifest as acute kidney injury, particularly in patients with pre-existing renal impairment, those receiving high doses or prolonged therapy, or concurrent use of other nephrotoxic agents (e.g., aminoglycosides, NSAIDs). Close monitoring of renal function through serum creatinine and urine output is imperative, with dose adjustments made based on renal clearance. Ototoxicity, characterized by hearing loss or tinnitus, is a rare but serious adverse effect, predominantly associated with high trough concentrations or concomitant administration of other ototoxic drugs; audiometric monitoring may be necessary in high-risk individuals. Furthermore, rapid intravenous infusion can precipitate 'Red Man Syndrome,' a histamine-mediated reaction that can cause severe flushing, rash, pruritus, tachycardia, and hypotension, emphasizing the critical importance of infusing vancomycin slowly over at least 60 minutes and considering antihistamine pre-treatment. These significant risks underscore the necessity of therapeutic drug monitoring (TDM) and individualized patient assessment throughout the course of vancomycin therapy.
- Several critical warnings are associated with vancomycin use.
- Renal impairment necessitates careful dosage adjustments and vigilant monitoring of renal function, including serum creatinine and blood urea nitrogen, to prevent drug accumulation and nephrotoxicity.
- Patients with pre-existing hearing loss or those receiving other ototoxic medications (e.
- g.
- , aminoglycosides) should be closely monitored for signs of ototoxicity, as vancomycin can exacerbate this condition.
- Rapid intravenous administration can induce 'Red Man Syndrome,' requiring infusion over at least 60 minutes and potentially prophylactic antihistamine administration.
- Prolonged use of vancomycin may lead to the overgrowth of non-susceptible organisms, including fungi, necessitating careful observation for superinfections.
- Cases of severe dermatologic reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS syndrome, have been reported, though rarely.
- Oral vancomycin is not effective for systemic infections due to poor absorption and should only be used for *Clostridioides difficile*-associated diarrhea.
How it Works (Mechanism of Action)
Vancomycin is a tricyclic glycopeptide antibiotic that exerts its bactericidal effect by inhibiting bacterial cell wall synthesis in susceptible Gram-positive organisms. Unlike beta-lactam antibiotics, which target penicillin-binding proteins, vancomycin acts earlier in the cell wall synthesis pathway. It specifically binds with high affinity to the D-Ala-D-Ala terminus of the peptidoglycan precursor units (N-acetylmuramic acid and N-acetylglucosamine peptide side chains), sterically hindering transglycosylation and transpeptidation reactions. This binding prevents the incorporation of new peptidoglycan units into the growing cell wall, leading to weakened and incomplete cell walls, ultimately causing osmotic lysis and bacterial death. Its unique mechanism of action is crucial for its efficacy against multi-drug resistant Gram-positive bacteria, particularly MRSA, as it bypasses the mechanisms of resistance associated with beta-lactamases and altered penicillin-binding proteins.